SymBio Pharmaceuticals Limited (4582) said EVO FUND exercised 43,000 of its 70th series stock acquisition rights in September 2026, receiving 4,300,000 new shares, or 9.0% of the 480,000 rights issued.
The rights, allotted to EVO FUND through a third-party allotment and issued on Sept. 2, carry an exercise price revision clause. The exercise price moved between ¥53 and ¥71 during the month. The largest single-day exercise came on Sept. 30, when 12,000 rights were exercised at ¥55 for 1,200,000 shares, followed by Sept. 17, with 9,500 rights exercised at ¥53 for 950,000 shares. All shares delivered were newly issued; no treasury shares were transferred.
| Item | Figure |
|---|---|
| Unexercised rights, Sept. 2 | 480,000 |
| Unexercised rights, end-September | 437,000 |
| September exercise price range | ¥53-¥71 |
| Exercise-restriction ratio | 5.4% |
The company had 80,247,210 shares outstanding as of Sept. 2, including 91,319 treasury shares. Shares delivered across all series amounted to 5.4% of listed shares as of the payment date, as calculated under Article 434 of the Tokyo Stock Exchange's listing rules. The purchase agreement with EVO FUND exempts exercises from the ban on excess exercise when the exercise price is at or above the closing price on Aug. 17, 2026, the date the issuance was resolved.
The 71st series rights, also issued to EVO FUND on Sept. 2, had their exercise price revised in line with the 70th series but cannot be exercised until the company instructs EVO FUND to begin, so the company omitted their monthly disclosure. Details are in the company's Aug. 17 announcement, which also covered an unsecured bond facility agreement and the issuance of its second series of privately placed unsecured bonds.
| Hikari Tsushin, Inc. | |
| Offer price | ¥1,000 per common share |
| M&A / TOB | 1 |
| Guidance | 0 |
| Buybacks | 0 |
| Dividends | 0 |
| Capital | 0 |
| Earnings | 0 |
| People | 0 |
Summaries of public disclosures by Japanese listed companies. Not investment advice; accuracy not guaranteed. Figures and dates in the TDnet originals prevail.
本站內容為日本上市公司公開開示之摘要整理，非投資建議，亦不保證正確。數字與日程以 TDnet 原文為準。
本サイトは日本の上場企業の適時開示を要約したものであり、投資助言ではありません。正確性は保証しません。数値・日程は TDnet の原文が優先します。